Brought to you by:

Sino Biopharmaceutical

AZ
Biotech

AstraZeneca pens $2.1B deal for challenger to Merck’s Ohtuvayre

AstraZeneca is paying $200 million upfront for ex-China rights to a late-phase challenger to Merck & Co.’s COPD drug Ohtuvayre.
Nick Paul Taylor Jul 8, 2026 5:00am
merck

AACR: Merck unveils PD-1xVEGF bispecific data in NSCLC

Apr 17, 2026 3:00pm
Sanofi
Favicon Fierce Pharma

Sanofi inks $1.5B deal for Sino Biopharm's novel asset

Mar 4, 2026 3:00am
Robot Holding Shopping Cart With Cardboard Boxes

AI-driven Formation snaps up oral autoimmune asset in $500M play

Jan 29, 2026 1:20pm
A chessboard with blocks that read MA

Sino Biopharm buys Merck’s PD-1xVEGF bispecific partner LaNova

Jul 15, 2025 10:16am
shooting star over mountain at night

F-star breaks free from invoX after $161M acquisition

Apr 4, 2025 10:03am